Leerink Partners Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its target price raised by analysts at Leerink Partners from $45.00 to $52.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners‘s price objective indicates a potential upside of 24.77% from the company’s previous close.

A number of other analysts have also commented on TEVA. Zacks Research lowered Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. TD Cowen increased their price objective on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday. UBS Group raised their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Oppenheimer lifted their target price on Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $47.23.

Teva Pharmaceutical Industries Stock Down 0.4%

TEVA stock traded down $0.17 during midday trading on Thursday, reaching $41.68. 13,632,476 shares of the company’s stock traded hands, compared to its average volume of 6,841,347. The company has a market cap of $48.56 billion, a price-to-earnings ratio of 96.92, a P/E/G ratio of 3.89 and a beta of 0.97. The firm’s fifty day moving average price is $39.32 and its 200-day moving average price is $34.68. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. Teva Pharmaceutical Industries has a 52 week low of $23.61 and a 52 week high of $43.34.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.22%. The company had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the business posted $0.78 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.00 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Roberto Mignone sold 367,600 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.54% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently modified their holdings of the business. Keybank National Association OH grew its holdings in shares of Teva Pharmaceutical Industries by 3.6% in the third quarter. Keybank National Association OH now owns 21,276 shares of the company’s stock valued at $843,000 after acquiring an additional 744 shares in the last quarter. AlphaCore Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $1,164,000. Fulcrum Asset Management LLP bought a new stake in Teva Pharmaceutical Industries during the third quarter worth $803,000. M Holdings Securities Inc. bought a new stake in Teva Pharmaceutical Industries during the third quarter worth $637,000. Finally, Brighton Jones LLC bought a new stake in Teva Pharmaceutical Industries during the third quarter worth $227,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q3 beat and raised outlook: Teva reported adjusted earnings of $0.86 per share versus $0.72 expected, and revenue of $4.40 billion versus $4.23 billion expected. Strong branded-drug sales helped the company raise its 2026 revenue and product-sales outlook. Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up
• Positive Sentiment: More optimistic analyst targets: TD Cowen raised its price target to $57 from $55 and kept a Buy rating. HC Wainwright also has a Buy rating, a $52 target, and forecasts 2027 EPS of $3.03. TD Cowen stock recommendations
• Positive Sentiment: Biosimilar portfolio expansion: Teva and Samsung Bioepis agreed to commercialize two FDA-approved biosimilars in the U.S., potentially adding products to Teva’s growth portfolio. Teva and Samsung Enter License and Commercialization Agreement
• Neutral Sentiment: Revenue remains a concern: Despite beating estimates, Q3 revenue declined 1.9% year over year, underscoring ongoing pressure even as the outlook improved. Teva stock: Q3 revenue slips as 2026 outlook rises
• Negative Sentiment: Clinical setback: Teva stopped its Phase 2 emrusolmin study after an interim review found insufficient efficacy. The company reported no safety concerns, but the decision removes a potential development opportunity. Why Is Teva Dropping a Drug Trial While Raising Its Outlook?

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company is one of the world’s largest producers of generic medicines and develops, manufactures and distributes prescription products across a broad range of therapeutic areas.

Teva’s portfolio includes generic medicines, specialty pharmaceuticals, biosimilars, active pharmaceutical ingredients and over-the-counter products. Its specialty medicines include treatments for neurological and movement disorders, respiratory conditions, migraine and other chronic diseases.